Find out which companies are dominating the industry and how to invest in them. Here are the top 10 CBD oil stocks to buy right now. The FDA’s approval of CBD can change the trajectory of these stocks quickly. If regulators get out of the way, these companies could soar. An in-depth look at the leading CBD stocks in the U.S stock market this year. Here’s what you need to know.
Best CBD Stocks to Buy: Top Ten Picks
With the growing popularity of medical marijuana across North America, many investors consider investing in stock-exchange listed companies. Investing in CBD stocks is a good idea if you’re looking for an investment with high course potential. Many different companies produce CBD products, and they all have their strengths and weaknesses. As someone who has done extensive research on the best cbd stocks to invest in, I will list my top 10 favorite companies for 2022 listed on NYSE and Nasdaq.
Keep in mind, CDB stocks are currently not in investors focus, and many of them are at longer-term lows right now. It needs to become an attractive investment field with more media dominance again before investments become worthwhile again.
Transparency: We may get compensated when you click on links in this article.
We’ve added current analyst estimates and company fundamentals to each company in the list using the fundamental analysis platform Stock Rover. You can use the free 14-day Stock Rover trial to check the most recent statistics, peers and stock analysis.
What are CBD Oil Stocks
CBD oil stocks refer to companies that produce and distribute CBD products. Companies like these are usually best suited for long-term investments because they have high potential growth over the next decade or more.
What is CDB Oil
CBD oil is a type of natural herb that has been used for many different purposes, including medical and recreational. CBD oils are typically extracted from hemp plants, making them legal in the United States under federal law.
What Brokers to Use to Buy CDB Oil Stocks
The best brokers to buy CDB oil stocks with are either TD Ameritrade or E*TRADE. They’re both straightforward to use and have many great tools that will make investing easier for beginners.
The Best CDB Stocks to Buy
Table of Contents
1. Jazz Pharmaceuticals (JAZZ)
The Ireland-domiciled biopharma company Jazz Pharmaceuticals focuses on treatments for indications in neuroscience, sleeping disorders and hematology-oncology. Jazz Pharmaceuticals still has a negative EPS of -5.46 with a market cap of $10.5 billion. In December 2021, the stock hit a mid-term low at $117.64 and then started a rally to nearly $170 in April 2022.
2. Constellation Brands (STZ)
Cannabis investing ideas also lead to this company with a currently neutral to positive market sentiment. Constellation Brands currently has projected quarterly revenue of 83 million and estimated earnings per share of $1.55.
Constellation Brands is a global leader in beer, wine and spirits with a wide variety of popular brands like Corona Extra and Ballast Point.
Constellation Brands made an investment into Canopy Growth Corporation (WEED) for $191 million worth a few years ago due to the potential growth that cannabis holds. Constellation Brands acquired a 40% ownership stake in Canopy Growth and became the third-largest investor in the cannabis industry. The investments were the right decision, and the stock price went up significantly since.
After forming a mid-term low at $104.28 in March 2020, the price per share increased to a new all-time high in April 2022 at $261.52.
3. AbbVie (ABBV)
AbbVie is a company with a market cap of $200 billion and is a science-led global healthcare company formed in 2013 by the acquisition of Abbott. AbbVie’s product portfolio includes more than 125 products, including pharmaceutical and over-the-counter medications and CBD oil. The stock had a great run from the $60 level in 2000 and market a all-time high in April 2022 at $175.91.
4. Altria (MO)
Altria is a significant producer of tobacco products and has invested in cannabis companies in the past. They have made investments from over $200 million to an equity stake in Cronos Group Inc. a few years back, which is one of the largest Canadian cannabis producers. Not only do they own these stocks, but they also sell cigarettes as well, and the growth potential is enormous. The stock formed a mid-term low at $30.95 in March 2020, and is now trading at $55.23.
5. Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutics to treat rare, chronic inflammatory diseases that are often difficult to treat with existing therapies. CRBP is still Nasdaq listed but might get OTC listed when it remains trading below $1. Right now, the stock is trading at $0.35.
6. Tilray Inc (TLRY)
Tilray is a Canadian company that produces and sells cannabis products, both medical marijuana. They’re best known for being the first company to legally export cannabis from North America for medical purposes through Europe (Greece). The latest news is that they have entered the world of cannabis recreation. The company is focused on research and development, which has allowed them to offer new products like their High CBD Oil Drops for anxiety relief or insomnia issues. They’re also well-known in Canada because all medical marijuana patients are registered with Tilray’s online system called CanvasRx. Many day traders trade Tilray shares due to its high volatile price action during market hours. The price per share is at $5.3 right now.
7. HEXO Corp. Common Shares (HEXO)
HEXO Corp. is a Canadian cannabis company focused on distributing world-class products within the adult-use and medical markets. HEXO Corp. is one of the leading exporters in Canada’s burgeoning cannabis industry to countries around the world where marijuana is legalized for medicinal or recreational purposes. Like CRBP, the stock is trading below $1 for a while (at $0.41 right now) and might get delisted from Nasdaq.
8. Cronos Group Inc. (CRON)
Cronos Group Inc. is a company focused on medical marijuana and recreational cannabis for adult use. They’re best known for producing, selling, and marketing products in Canada, Germany, Israel, Italy and Australia. Cronos Group announced that they were partnering with Ginkgo Bioworks to engineer yeast that produces cannabinoids genetically. The good thing with Cronos is that they have a lot of room to grow based on solid company fundamentals. Right now, the stock is trading at $3.08.
9. Aurora Cannabis (ACB)
Aurora Cannabis is a Canadian company that is a producer and seller of medical cannabis products. They’re best known for being the first marijuana company to be listed on an American stock exchange. Recently Aurora Cannabis announced that they were entering the European market by acquiring a German company. The stock is currently trading at $3.1. They recently had a formal bid accepted and are set to acquire CanniMed Therapeutics, which has experts speculating that the company could be worth $600 million. Aurora is one of those stocks best to buy because it’s still undervalued due to its marijuana production being in Canada. Still, they have made their intentions known for expansion into Europe unfolding additional potential.
10. ETFMG Alternative Harvest ETF (MJ)
You have already read about the top favorite CBD stocks to buy. Investors can also participate in CBD oil stock growth by buying the exchange-traded fund. The ETFMG Alternative Harvest ETF is a fund that invests in companies operating in the global cannabis industry. The ETFMG Alternative Harvest ETF is an umbrella term as it includes a variety of sectors. The ETF is currently trading at an 5-year low at $8.45.
Introduction to Marijuana Stocks
Marijuana stocks are made up to become a thriving and profitable industry. With the legalization of cannabis in Canada and previously in the United States, stocks are bound to arise.
Cannabis companies are not only for those in North America but all over the world, from Europe to Africa. Cannabis stocks are an opportunity that investors can’t afford to miss out on now! One of the best next best things in speculative investing is CBD oil stocks and similar companies. With marijuana becoming more mainstream, there will be a rise of people looking to invest in this sector.
Marijuana Stocks With the Most Momentum
Momentum investing is when you invest in stocks that have gone up faster than the market. If a stock has risen more than the market, momentum investors think it will continue to do so because of factors that caused it to go up. Investors want to buy stocks with high returns and count on a trend continuation in the subsequent months for the stock. The concept is to analyze data of potential Marijuana stocks to buy via Nasdaq, NYSE or even OTC. While investments in ETFs are often compound profits over the years by contribution to the ETFs, specific investing in Marijuana momentum stocks aim for short-term growth with higher risk and higher potential. Keeping an eye on company financials, earnings, cannabis use, and news is important too.
The Role of the Farm Bill
The farm bill was passed to legalize the production and sale of hemp. This is a major step in the right direction for marijuana stocks and will help make it more mainstream and provide employment opportunities with its legalization. The best thing about investing in cannabis companies is that you can get an ownership stake through stock buybacks or dividends.
How to Gain Access to the Global Cannabis Stock Market
An online broker allows you to invest in marijuana stocks from around the world. It is a great way to diversify your portfolio, find new opportunities, and provide liquidity for international investments. By doing this, you can also invest in companies involved with CBD oil processing and production.
Conclusion About the Best CBD Stocks to Buy
Marijuana stocks are a great way to diversify your portfolio and find new opportunities. Investing in them provides liquidity for international investments and owning an ownership stake through stock buybacks or dividends.
Cbd stocks are a wise investment choice that is forecasted to grow exponentially in the future. The product development recently has resulted in a massive uptick in the interest of CBD stocks, and as such, it is crucial to stay up-to-date with this market.
The best CBD stocks have shown strong revenue growth over the past five years and are positioned for rapid future growth due to their product development. The earnings per share are solid for many companies in the marijuana industry, and more and more brands enter the profitable cannabis market.
It is essential to diversify your portfolio, so it is wise to invest in a range of stocks. Marijuana-focused companies with solid fundamentals, which will allow investors the best returns for their investment at a reasonable stock price, are a good starting point.
About the author: Alexander is the founder of daytradingz.com and has 20 years of experience in the financial markets. He aims to make trading and investing easy to understand for everybody, and has been quoted on Benzinga, Business Insider and GOBankingRates.
Top Three CBD Stocks to Watch Closely in 2022
There’s a lot of overlap between CBD stocks and pot stocks. Which, of course, makes perfect sense. The cannabis plant has scores of active chemical compounds in it. One of them is delta-9-tetrahydrocannabinol (THC). This is the compound that gets stoners… stoned.
The other big one is cannabidiol (CBD). This compound has no psychoactive properties. But there are a whole lot of potential health benefits. Now, marijuana producers have no need to weed out the CBD. However, companies focusing on CBD do have to keep out the THC if they want to sell their products over the counter. But it’s not terribly difficult if the CBD is derived from industrial hemp. Which, unlike marijuana, is not a controlled substance.
To complicate matters even further, the Food & Drug Administration (FDA) hasn’t compiled a lot of information on CBD. So, it lingers in a state of near-limbo… due, if nothing else, to its close proximity to THC. It’s not quite legal. But based on how easy it is to find CBD products at the local pharmacy, grocery store and coffee shop; it’s obviously not illegal either. However, its legal status can depend on which state you live in.
Here’s how that works…
In 2018, President Trump signed the Agriculture Improvement Act. This is better known as the 2018 Farm Bill. In that act, there was a section that removed hemp from the Controlled Substances Act. Thanks to that bill, CBD – which can be extracted from hemp – was deemed legal on the federal level. The bill targeted the agricultural aspect, though. Compounds extracted from hemp – à la CBD – aren’t privy to the same complete green light as hemp itself. So CBD operates in a mixed jurisdictional realm.
Warning: More Politics & Science Ahead
The federal government won’t arrest folks for growing hemp anymore. Extracting CBD or possessing it isn’t a federal crime anymore either. Well, if there’s less than 0.3% THC content. But not all states see eye to eye with the feds. Some states still want to see more evidence of the benefits and lack of drawbacks. And in some states, CBD remains blacklisted.
But here’s a big feather in the cap of CBD. The Food & Drug Administration has approved a CBD product to treat Lennox-Gastaut syndrome. It’s also been approved to treat Dravet syndrome. To paraphrase, it’s been proven to help those suffering from certain types of epilepsy.
When Greenwich Biosciences received approval for its epilepsy drug, Epidiolex, it was initially considered a controlled substance. Simply because it was derived from marijuana. But when the company requested it be removed from the controlled substances list, the Drug Enforcement Agency (DEA) agreed. This was a big deal because it was the first time the DEA removed any type of cannabis compound from Schedule 1. And this could eventually prove to be a tipping point.
Regardless of what the FDA says, studies have shown that CBD can help to treat insomnia and anxiety. And it can even act as an antidepressant. It has also helped those dealing with chemotherapy and can treat acne. Nonetheless, not everyone remains sold on the prospect of CBD. And at least part of the problem is bad actors.
The FDA had to warn folks to stop claiming CBD could cure the coronavirus. Also, it probably can’t fix “dryness and frizz” in hair or prevent it from turning gray. That’s the kind of claim the FDA is looking out for. And more importantly, we know at this point that it can do some positive things. And here are three companies proving it…
Three CBD Stocks Worth Investing In
- GW Pharmaceuticals (Nasdaq: GWPH)
- Charlotte’s Web Holdings (OTC: CWBHF)
- CV Sciences (OTC: CVSI)
We’ll start with the big one. GW has essentially built its future and reputation on prescription CBD products. It’s the parent company of Greenwich Biosciences – the maker of Epidiolex. It has also received approval of its Sativex therapy in several countries. It’s a multiple sclerosis treatment that is a cannabis-extracted spray containing CBD. It’s used to treat multiple sclerosis.
Even right now, as some of its therapies remain in limbo, GW stock is pricey. But it’s proven to be insulted from the price swings of the marijuana market. The company also has an impressive pipeline of therapies in the works. And approval of them could send this CBD stock skyrocketing.
Charlotte’s Web Holdings
Charlotte’s Web Holdings can be viewed as the indicator of the CBD industry. If CBD sales are on the rise, this CBD stock will be one of the first to indicate it.
The company recently acquired the topical treatment manufacturer Abacus Health Products with the intention of expanding its product line. The plans have already paid off, with net revenue up 1% in 2021. And increasing product lines should only further help the company’s bottom line. This Colorado-based company has deals with major retailers, including Kroger (NYSE: KR), The Vitamin Shoppe and CVS (NYSE: CVS). Once the FDA clears up the regulatory uncertainty surrounding CBD food products, you can expect this stock to soar.
This company has two distinct segments: consumer products and drug development. The consumer products one is straightforward. It focuses on manufacturing, marketing and selling CBD products. On the other hand, the pharmaceutical division is constantly trying to push the needle and develop novel CBD-based therapeutics. But the company already has the top-selling hemp-derived CBD oil on the market.
CV Sciences’ PlusCBD Oil was the first supplement to receive “generally recognized as safe” (GRAS) status. And the company continues to grow its product line. The company is currently developing synthetic CBD-based medicine and is pursuing FDA approval for drugs. But again, once regulations around CBD are relaxed, this CBD stock is expected to see a major bounce.
The Bottom Line on CBD Stocks
Bills have been introduced to amend the Federal Food, Drug and Cosmetic Act and its regulations of hemp-derived CBD. The best guess as to why they haven’t moved forward is that Congress got distracted by the pandemic. But they should be picked up again. If the FDA finally gets out of the way, these CBD stocks are going to be major beneficiaries.
Unfortunately, for now the prospects of this budding industry are still tied up in politics. And the FDA’s approval (or lack thereof) can change the trajectory of these stocks quickly.
About Matthew Makowski
Matthew Makowski is a senior research analyst and writer at Investment U. He has been studying and writing about the markets for 20 years. Equally comfortable identifying value stocks as he is discounts in the crypto markets, Matthew began mining Bitcoin in 2011 and has since honed his focus on the cryptocurrency markets as a whole. He is a graduate of Rutgers University and lives in Colorado with his dogs Dorito and Pretzel.
Investing in CBD Stocks
Sometimes the best time to invest in a relatively new market is after the initial euphoria evaporates. That could very well be the case with investing in CBD stocks.
CBD is short for cannabidiol, which is a chemical found in the cannabis plant. CBD doesn’t produce a high but has been found to have therapeutic benefits.
The U.S. legalized hemp-derived CBD at the federal level with the 2018 Farm Bill. The mere anticipation of the passage of this legislation stoked investors’ interest in the stocks of companies involved in the CBD industry.
Although federal legalization served as a key milestone, the U.S. Food and Drug Administration (FDA) still hasn’t finalized regulations for CBD food supplements. As a result, the CBD opportunity in the U.S. hasn’t delivered on investors’ lofty ambitions — at least not yet. However, the pressure is mounting for CBD regulations to be eased. Even the U.S. Congress has gotten involved with bill proposals to change the federal regulation of CBD products.
The CBD market could expand in the not-too-distant future with the finalization of regulations. Now could be a great time for investors to check out CBD stocks. Here are five CBD stocks to consider in 2022.
|Canopy Growth (NASDAQ:CGC)||$3 billion||Canadian cannabis producer with U.S. CBD operations.|
|Charlotte’s Web Holdings (OTC:CWBHF)||$172 million||Leading CBD products company.|
|Cresco Labs (OTC:CRLBF)||$2.1 billion||U.S. cannabis operator that markets CBD products.|
|Jazz Pharmaceuticals (NASDAQ:JAZZ)||$8.5 billion||Pharmaceutical company with the first FDA-approved CBD drug.|
|The Valens Company (NASDAQ:VLNCF)||$166 million||Canadian company that provides extraction services used to produce CBD and cannabis derivative products.|
For a while, Canopy Growth ranked as the biggest marijuana stock in the world based on market cap. It remains one of the largest companies in the cannabis industry with top-tier positions in the Canadian medical and recreational marijuana markets and the German medical cannabis market.
Canopy Growth can’t enter the U.S. cannabis market and maintain its listing on a major U.S. stock exchange as long as marijuana is illegal at the federal level. However, the company is already a player in the U.S. hemp-derived CBD market.
In 2019, Canopy Growth teamed up with businesswoman and TV celebrity Martha Stewart to develop CBD products for the U.S. market. The company now has a line of CBD brands with Stewart. It also has other CBD products that include Whisl, the No. 1 CBD-only vape in the U.S. market.
Canopy Growth isn’t profitable yet. However, it does have a large cash stockpile, thanks in large part to investments by beverage giant Constellation Brands (NYSE:STZ), the company’s biggest shareholder.
The CBD opportunity is only a secondary reason to consider this stock. The primary potential catalyst for Canopy Growth is the prospect that U.S. federal cannabis laws will be changed and allow the company to enter the lucrative U.S. cannabis market.
Charlotte’s Web Holdings
If you’re looking for a pure-play CBD stock, Charlotte’s Web could be right up your alley. The company pioneered the hemp CBD industry in 2011, and it still ranks No. 1 based on market share.
Charlotte’s Web markets a wide range of CBD products. From bath and beauty to ingestibles and topicals, the company covers all the bases when it comes to CBD. It even sells CBD products for pets.
The company’s CBD products are available at more than 14,000 retail outlets. About 8,000 healthcare practitioners also distribute Charlotte’s Web’s products, and the company has a strong online presence. More than half of its total revenue stems from direct-to-consumer e-commerce sales.
Charlotte’s Web isn’t resting on its laurels. It plans to launch CBD beverages in the second half of 2022. Market researcher Brightfield Group projects that the CBD beverage market will reach $1.3 billion in 2026, up from $245 million in 2021.
However, Charlotte’s Web’s stock performance over the past couple of years has been disappointing. But the company now has a new CEO with former Bacardi executive Jacques Tortoroli taking the helm in December 2021. The potential for the finalization of regulations regarding CBD dietary supplements could be just what the stock needs to mount a major comeback.
Cresco Labs is a U.S.-based cannabis operator that markets recreational and medical cannabis products in 10 states, all of which rank among the 20 most-populated in the U.S. (and with seven in the top 10).
The company isn’t just a cannabis producer and retailer. Cresco also is the No. 1 U.S. wholesaler of branded cannabis products containing CBD, including its Wonder gummies.
Cresco has achieved tremendous success in recent years. The company’s revenue has grown significantly, both organically and through acquisitions. It’s consistently profitable. Cresco’s solid balance sheet should also enable it to continue expanding into new markets.
Probably the biggest knock against Cresco is that the company can’t list its shares on a major U.S. stock exchange as long as marijuana remains illegal at the federal level. However, this limitation also is a key factor behind the stock’s attractive valuation compared to Canadian pot stocks.
You might be surprised to find a pharmaceutical stock listed among the top CBD stocks to consider. But Jazz Pharmaceuticals has a direct and important connection with CBD. In 2018, the company’s Epidiolex became the first CBD product made from the cannabis plant to win FDA approval.
Jazz actually didn’t own Epidiolex at that time. It acquired GW Pharmaceuticals, which developed the CBD drug to treat epileptic seizures, for $6.7 billion in 2021 .
Epidiolex is still a long way from generating annual sales of $1 billion or more, as some analysts projected after it was first approved in the U.S. However, sales continue to pick up as the drug launches in additional European countries.
Jazz also has other growth drivers in its lineup. Sleep disorder drug Xywav is gaining momentum. Sales are soaring for another sleep disorder drug, Sunosi, as well as blood cancer drug Rylaze and lung cancer drug Zepzelca.
Related Investing Topics
Investing in Marijuana Stocks
The continued legalization of marijuana means growth for companies in this sector.
Investing in Psychedelic Stocks
It turns out that “magic mushrooms” may have medical applications.
Investing in Biotech Stocks in 2022
These companies create drugs and treatments for some of the biggest medical problems of our time.
Investing in Healthcare Stocks
Healthcare is a universal need. Companies in this broad-based sector can produce healthy returns.
The Valens Company
One of the important steps in investing in marijuana stocks is to understand the different types of companies. Ancillary businesses that support the industry can sometimes have even more attractive prospects than pure plays. The Valens Company is a good example.
Valens is the largest third-party extraction company serving the Canadian cannabis industry. It uses different methods to extract cannabinoids (including CBD) from cannabis. Valens also markets its own cannabis products, which is part of its strategy to transition into a leading cannabis consumer packaged goods company.
The company’s Green Roads already ranks among the top 10 CBD brands in the U.S. Green Roads products are available in about 7,000 retail locations. Valens hopes to also achieve success in Canada if over-the-counter CBD sales are permitted in the country.
Like most Canadian cannabis-related stocks, Valens hasn’t made investors happy over the past year. However, its shares trade at a more attractive valuation than most U.S. and Canadian cannabis stocks.
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Constellation Brands, Cresco Labs Inc., and The Valens Company Inc. The Motley Fool recommends Charlotte’s Web and Charlotte’s Web Holdings. The Motley Fool has a disclosure policy.